Between 1998 and 2003, the budget of the National
Institutes of Health (NIH) rose from $13 billion to more than $27
billion in a plan known as "the doubling.” Now that the tsunami of
cash has receded, many life scientists--especially those in the
early phase of their careers--have found conditions no better, and
in some ways worse, than before the process began.
This unwelcome outcome has not dampened politicians’ enthusiasm
for the symbolism of multiplying by two. The American
Competitiveness Initiative (ACI), a presidential plan aimed at
retaining the nation’s technological edge, foresees just such a
burst of largess for three agencies active in physical science: the
National Science Foundation (NSF), the Department of Energy’s
(DOE's) Office of Science, and the National Institute of Standards
and Technology (NIST). But will the blast of cash bring the same
problems and disappointments experienced in the life sciences?
“The glut of graduate students enticed by the growing support a
few years ago have since found it difficult to get their own work
funded … and the sudden deceleration in funding has left many
researchers feeling slighted even though their funding grew by
leaps and bounds in the past decade.” --Yuval Levin
Too much too soon
The NIH doubling did do a lot of good, providing billions of
dollars for basic and clinical research and establishing a new,
much higher baseline for funding. Still, “both the way Congress has
expanded the NIH budget and the way NIH has made use of its new
funds offer important cautionary lessons,” writes Yuval Levin, a
former associate director of the White House Domestic Policy
Council, in an
article inThe New Atlantis . He writes that the infusion
of money was “far too rapid, and not adequately tied to structural
reforms that might enable NIH to best make use of its growing
resources.” Fifteen percent hikes for each of 5 years “built
expectations and momentum that set the agency up for disappointment
when the doubling was done,” he writes.
The number of academic positions in the life sciences increased,
especially at medical schools, and nonacademic employment grew even
faster, according to an
analysis by economist Paula Stephan of Georgia State University
in Atlanta. The likelihood that a young American-trained Ph.D.
would land that coveted tenure-track job was the same in 2003 as it
was a decade earlier; however, the new academic posts are supported
mainly by soft money and are off the tenure track. Many are good
jobs in terms of income and opportunities to do research, but they
are dependent on grant renewals.
Meanwhile, the number of life scientists unemployed, out of the
labor force, or in part-time posts also grew. For scientists in
academe, universities’ expectations about the number of grants they
should win increased, as did the number of proposals submitted to
NIH. Many established researchers hiked the number of grants they
receive and the number of scientists working in their labs, but
newer investigators saw virtually no rise in funding through the
Research Project Grant Program (R01) grants considered crucial to
establishing an independent scientific career, Stephan found.
“When everybody heard the budget was doubling, … many medical
schools and arts and sciences programs with strong and
not-so-strong biomedical programs … really decided to invest in
their programs,” Stephan says in an interview. “As a country we
really over-responded.” The result? It became “harder … to get
money. … Success rates have really fallen”--especially for new
investigators, Stephan says. Those “really hurt…are young people,”
as an increasing share of NIH support has gone to older
researchers, she says.
The 5-year doubling period left many younger scientists stranded
because, Levin notes, it was too short a time period for them to
earn a Ph.D., win tenure, or bring a newly funded research program
to fruition before money became tight. “The glut of graduate
students"--and postdocs--"enticed by the growing support a few
years ago have since found it difficult to get their own work
funded … and the sudden deceleration in funding has left many
researchers feeling slighted even though their funding grew by
leaps and bounds in the past decade,” he writes.
Still, “it’s hard to blame the NIH just because of the way it
has to be answerable to Congress,” Levin says in an interview.
NIH’s plethora of institutes and centers mostly exist because “some
member of Congress has a pet cause and says that NIH should focus
on it,” explains Levin. The idea for the doubling also seems to
have had more to do with political symbolism than with any reasoned
analysis of the long-term needs of American science. “Medical
research is the sole hope we can provide to millions of Americans,”
wrote Senator Tom Harkins (D–IA) in 2002, explaining why he and
Senator Arlen Specter (R–PA) “set the ambitious goal of doubling
America’s investment in … the life-saving research supported by NIH
and conducted at leading research institutions like the University
of Iowa and Iowa State.”
But the doubling missed the opportunity to rationalize NIH’s
tangle of entities, Levin notes. Reorganizing the vast agency
around broad scientific themes rather than historic happenstance
would cut confusion, increase flexibility, and save money that
could move from redundant bureaucracy to research, he says. Also
needed, Stephan suggests, is new thinking about how to staff labs
so that fewer frustrated new job seekers are produced.
Protective factors
As the doubling of the budgets of the three ACI agencies gets
underway, several factors may protect the physical sciences from a
troubling denouement. First, it is planned for 10 rather than 5
years, providing less abrupt growth and more time before the
acceleration ends, allowing grad students to finish degrees,
postdocs to find jobs, new faculty to achieve tenure, and newly
established labs to build track records. Second, the sums involved
are less massive and therefore can’t lure as many young people into
a potentially futile effort to launch scientific careers. The total
NSF budget request for fiscal year (FY) 2008 is $6.4 billion, up
8.7% from last year. For the Office of Science, the 2008 request
totals $4.4 billion, and for the core programs at NIST that will
undergo doubling, the 2008 request is $600 million.
The way two of these agencies spend their money, furthermore, is
less likely to flood the job market. Eighty percent of NIH’s funds
go to 50,000 competitive grants to principal investigators who
staff their labs with temporary labor--grad students and postdocs
who become part of a constant stream of new scientific-job seekers.
Although smaller, NSF works the same way as NIH; NSF expects to
make about 10,400
competitive awards in FY 2008, according to the American
Association for the Advancement of Science.
But DOE's Office of Science will spend only half its budget on
work by university researchers, with much of the rest going to its
ten national laboratories and research facilities, from Brookhaven
in New York state to the Pacific Northwest National Lab in
Washington state. NIST’s Scientific and Technical Research Services
is slated for a 12.8% increase, to $420 million, all of it going to
support NIST’s own labs and facilities in Maryland and Colorado,
with additional money for construction and new equipment. Both of
these agencies have postdocs--who, incidentally, are paid much more
than those dependent on NIH grants--but their facilities are
staffed by mostly long-term employees.
Which leads to a third major difference: the job market is
stronger for physical scientists than for life scientists, at least
for now. New physical science Ph.D.s are considerably less likely
to be postdocs, unemployed, or out of the job market than
biomedical Ph.D.s--and substantially more likely to get faculty or
industry jobs. Creating “a job market at least as large as the
added influx of graduate students you’re creating” is vital to
building the next generation of scientists, Levin says. Otherwise,
“you’re setting yourself up for the kind of deflating experience
that the NIH has, their recipients … genuinely angry about
declining budgets at a time that they’ve got enormous budgets. And
they’re not wrong,” he adds.
Whether a good result will emerge is as yet unclear. Apart from
the three ACI agencies and a few others, the outlook for federal
research and development funding is bleak, with the president’s
2008 budget proposing a drop in real dollars and substantial cuts
at a number of agencies. Some critics call the ACI doubling a
diversion to mask the overall decline in science spending. The key
to fostering research and nurturing a new generation of talent is
not, as the NIH experience shows, simply large infusions of
long-wished-for but short-term cash. Rather, it is steady
commitment over the long term. Once again, the former is underway.
The latter remains to be seen.
|
Beryl Lieff Benderly writes from Washington, D.C.
|
|
DOI: 10.1126/science.caredit.a0700099
|
Comments, suggestions? Please send your feedback to our editor .
|